FDA Releases Final Guidance for Abbreviated New Drug Applications for Synthetic Peptide Drug Products Referencing rDNA Origin Drugs

Summary

The FDA has released a final guidance for industry on abbreviated new drug applications for synthetic peptide drug products that refer to previously approved rDNA origin drugs, helping potential applicants determine when to submit an ANDA instead of a new drug application.